2,045 Shares in Charles River Laboratories International, Inc. (NYSE:CRL) Purchased by Trust Point Inc.

Trust Point Inc. purchased a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 2,045 shares of the medical research company's stock, valued at approximately $378,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in CRL. Cetera Investment Advisers lifted its holdings in shares of Charles River Laboratories International by 2.4% in the 2nd quarter. Cetera Investment Advisers now owns 9,969 shares of the medical research company's stock worth $2,059,000 after purchasing an additional 229 shares in the last quarter. Handelsbanken Fonder AB raised its holdings in Charles River Laboratories International by 18.4% during the third quarter. Handelsbanken Fonder AB now owns 12,237 shares of the medical research company's stock worth $2,410,000 after buying an additional 1,900 shares during the last quarter. Czech National Bank lifted its stake in shares of Charles River Laboratories International by 7.1% in the third quarter. Czech National Bank now owns 10,517 shares of the medical research company's stock valued at $2,072,000 after buying an additional 701 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Charles River Laboratories International by 22.6% during the third quarter. GAMMA Investing LLC now owns 1,041 shares of the medical research company's stock valued at $205,000 after buying an additional 192 shares during the last quarter. Finally, Fulton Bank N.A. increased its position in shares of Charles River Laboratories International by 2.8% during the third quarter. Fulton Bank N.A. now owns 3,396 shares of the medical research company's stock worth $669,000 after acquiring an additional 91 shares in the last quarter. Institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Trading Down 1.6 %

NYSE:CRL traded down $2.62 during mid-day trading on Friday, reaching $163.65. 564,421 shares of the company's stock traded hands, compared to its average volume of 1,002,698. The company has a 50 day moving average price of $180.61 and a 200-day moving average price of $193.44. The firm has a market capitalization of $8.37 billion, a price-to-earnings ratio of 20.48, a PEG ratio of 6.47 and a beta of 1.37. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14. Charles River Laboratories International, Inc. has a 12-month low of $159.65 and a 12-month high of $275.00.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The firm had revenue of $1.01 billion for the quarter, compared to analysts' expectations of $975.99 million. During the same period in the previous year, the firm earned $2.72 earnings per share. The business's revenue was down 1.6% compared to the same quarter last year. On average, sell-side analysts predict that Charles River Laboratories International, Inc. will post 10.16 earnings per share for the current year.

Wall Street Analysts Forecast Growth

CRL has been the subject of a number of analyst reports. Morgan Stanley cut their price target on Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating for the company in a research note on Wednesday. Evercore ISI lifted their target price on Charles River Laboratories International from $190.00 to $225.00 and gave the company an "in-line" rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. lowered their price target on Charles River Laboratories International from $215.00 to $175.00 and set a "neutral" rating for the company in a research report on Monday, February 3rd. TD Cowen lifted their price objective on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a "hold" rating in a report on Monday, November 11th. Finally, Redburn Atlantic initiated coverage on Charles River Laboratories International in a research note on Monday, October 14th. They issued a "sell" rating and a $151.00 target price on the stock. Three analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $200.79.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).